SG Americas Securities LLC Has $4.73 Million Position in BioNTech SE (NASDAQ:BNTX)

SG Americas Securities LLC lifted its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 412.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,470 shares of the company's stock after buying an additional 33,375 shares during the period. SG Americas Securities LLC's holdings in BioNTech were worth $4,726,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Baillie Gifford & Co. boosted its position in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company's stock worth $986,750,000 after acquiring an additional 31,773 shares during the period. FMR LLC boosted its holdings in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the period. Fred Alger Management LLC acquired a new stake in shares of BioNTech during the third quarter worth approximately $59,485,000. DekaBank Deutsche Girozentrale grew its position in BioNTech by 12.6% during the third quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company's stock valued at $56,886,000 after purchasing an additional 53,800 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its stake in BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company's stock valued at $37,103,000 after buying an additional 341,311 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analysts Set New Price Targets

BNTX has been the topic of several research analyst reports. BMO Capital Markets restated an "outperform" rating on shares of BioNTech in a report on Monday, December 2nd. Wells Fargo & Company initiated coverage on BioNTech in a research note on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 target price on the stock. Canaccord Genuity Group lifted their price target on BioNTech from $171.00 to $171.44 and gave the company a "buy" rating in a report on Wednesday, November 27th. HC Wainwright reissued a "buy" rating and issued a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Finally, Evercore ISI raised shares of BioNTech from an "in-line" rating to an "outperform" rating and raised their price objective for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Three analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech has a consensus rating of "Moderate Buy" and an average price target of $142.72.

BioNTech Stock Performance

NASDAQ:BNTX traded down $3.98 during mid-day trading on Friday, hitting $118.14. 695,434 shares of the company's stock traded hands, compared to its average volume of 569,360. The firm has a market capitalization of $28.32 billion, a price-to-earnings ratio of -56.26 and a beta of 0.18. The firm has a 50 day moving average of $115.78 and a two-hundred day moving average of $105.70. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same period in the prior year, the business earned $0.73 earnings per share. BioNTech's revenue for the quarter was up 38.9% compared to the same quarter last year. On average, equities analysts forecast that BioNTech SE will post -3.77 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.